BHCM
LFCR icon

Brevan Howard Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Brevan Howard Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-32,785
Closed -$174K – 1247
2024
Q1 		$174K Buy
+32,785
New +$234K ﹤0.01% 829

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

Brevan Howard Capital Management's LFCR Position: Q2 2024 in Review

Brevan Howard Capital Management sold out of Lifecore Biomedical (LFCR) in Q2 2024, closing a stake of 32,785 shares — an estimated $174K sold.

Brevan Howard Capital Management first reported a position in LFCR in Q1 2024 and held it in 1 quarter. The position peaked at $174K in Q1 2024. 75 funds tracked by Wall St. Rank hold LFCR as of Q2 2024.

  • Brevan Howard Capital Management reported no remaining Lifecore Biomedical position as of Q2 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 32,785 Lifecore Biomedical shares in Q2 2024, an estimated $174K.
  • Brevan Howard Capital Management first reported a position in Lifecore Biomedical in Q1 2024 and held it in 1 quarter.
  • Brevan Howard Capital Management's Lifecore Biomedical position peaked at $174K in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2024.

Based on Brevan Howard Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.